Skip to main content
SpringerLink
Log in

Intradermal Vaccination to Protect Against Yellow Fever and Influenza

  • Chapter
  • First Online:
Intradermal Immunization

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 351))

Abstract

The viral infections yellow fever and influenza can lead to large epidemics, which may deplete limited vaccine supplies. The intradermal vaccination route of yellow fever and influenza vaccines has received renewed attention, because it allows dose reduction without loss of efficacy. In this chapter, we review these two vaccines, the history of vaccine development, correlates of protection, immune response to vaccination and current knowledge concerning intradermal vaccination, including the immunological background, both in healthy subjects and immunocompromized individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Akondy RS, Monson ND, Miller JD et al (2009) The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 183:7919–7930

    Article  PubMed  CAS  Google Scholar 

  • Allan RS, Waithman J, Bedoui S et al (2006) Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25:153–162

    Article  PubMed  CAS  Google Scholar 

  • Appleby JC, Himmelweit F, Stuart-Harris CH (1951) Immunisation with influenza virus A vaccines, comparison of intradermal and subcutaneous routes. Lancet 1:1384–1387

    Article  PubMed  CAS  Google Scholar 

  • Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P (2009) Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 27:7304–7312

    Article  PubMed  CAS  Google Scholar 

  • Bains I, Antia R, Callard R, Yates AJ (2009) Quantifying the development of the peripheral naive CD4+ T-cell pool in humans. Blood 113:5480–5487

    Article  PubMed  CAS  Google Scholar 

  • Barwick R (2004) History of thymoma and yellow fever vaccination. Lancet 364:936

    Article  PubMed  Google Scholar 

  • Belshe RB, Newman FK, Cannon J et al (2004) Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351:2286–2294

    Article  PubMed  CAS  Google Scholar 

  • Beyer WE, de Bruijn IA, Palache AM, Westendorp RG, Osterhaus AD (1998) The plea against annual influenza vaccination? ‘The Hoskins’ Paradox’ revisited. Vaccine 16:1929–1932

    Article  PubMed  CAS  Google Scholar 

  • Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus AD (2004) Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 103:125–132

    Article  PubMed  CAS  Google Scholar 

  • Centers for Disease Control and Prevention (CDC) (2009) Pandemic influenza A (H1N1) virus infections—Chicago, Illinois, April–July 2009. MMWR Morb Mortal Wkly Rep 58(33):913–918

    Google Scholar 

  • Chlíbek R, Smetana J, Sindelár R, Cecetková B, Prymula R, Kohl I (2007) Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age—impact of risk factors. Epidemiol Mikrobiol Imunol 56:119–128

    PubMed  Google Scholar 

  • Cohen Stuart J, Hamann D, Borleffs J, Roos M, Miedema F, Boucher C, de Boer R (2002) Reconstitution of naive T cells during antiretroviral treatment of HIV-infected adults is dependent on age. AIDS 16:2263–2266

    Article  PubMed  CAS  Google Scholar 

  • Cubas R, Zhang S, Kwon S et al (2009) Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother 32:118–128

    Article  PubMed  Google Scholar 

  • de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol 115:63–73

    Google Scholar 

  • de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, van der Ende ME (2008) A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 197:292–294

    Article  PubMed  Google Scholar 

  • Douek DC, McFarland RD, Keiser PH et al (1998) Changes in thymic function with age and during the treatment of HIV infection. Nature 396:690–695

    Article  PubMed  CAS  Google Scholar 

  • Fox JP, Luty Kossobudski S, Fonseca da Cunha J (1943) Field studies on the immune response to 17D yellow fever virus. Relation to virus substrain, dose and route of inoculation. Am J Hyg 38:113–138

    Google Scholar 

  • Gaspar LP, Mendes YS, Yamamura AM et al (2008) Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 150:57–62

    Article  PubMed  CAS  Google Scholar 

  • Gaucher D, Therrien R, Kettaf N et al (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205:3119–3131

    Article  PubMed  CAS  Google Scholar 

  • Gelinck LBS, Teng YKO, Rimmelzwaan GF, Van den Bemt BJF, Kroon FP, Van Laar JM (2007) Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 66:1402–1403

    Article  PubMed  CAS  Google Scholar 

  • Gelinck LB, van den Bemt BJ, Marijt WA, van der Bijl AE, Visser LG, Cats HA, Rimmelzwaan GF, Kroon FP (2009) Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. Vaccine 27:2469–2474

    Article  PubMed  CAS  Google Scholar 

  • Glenn GM, Kenney RT (2006) Mass vaccination: solutions in the skin. Curr Top Microbiol Immunol 304:247–268

    Article  PubMed  CAS  Google Scholar 

  • Gould EA, Buckley A, Barrett ADT, Cammack N (1986) Neutralizing (54 K) and nonneutralizing (54 K and 48 K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol 67:591–595

    Article  PubMed  CAS  Google Scholar 

  • Greenberg ME, Lai MH, Hartel GF et al (2009) Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361:2405–2413

    Article  PubMed  CAS  Google Scholar 

  • He Y, Zhang J, Donahue C, Falo LD Jr (2006) Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 24:643–656

    Article  PubMed  CAS  Google Scholar 

  • Hepburn MJ, Kortepeter MG, Pittman PR, Boudreau EF, Mangiafico JA, Buck PA, Norris SL, Anderson EL (2006) Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 24:2843–2849

    Google Scholar 

  • Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, McKeirnan M, Salem H, Mills G, Reid J, Weber F, Saville M (2008) Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 198:650–658

    Article  PubMed  Google Scholar 

  • Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A (1979) Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ’s Hospital. Lancet 1:33–35

    Article  PubMed  CAS  Google Scholar 

  • Itano AA, McSorley SJ, Reinhardt RL, Ehst BD, Ingulli E, Rudensky AY et al (2003) Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19:47–57

    Article  PubMed  CAS  Google Scholar 

  • Jo YM, Song JY, Hwang IS, Lee J, Oh SC, Kim JS, Kim SR, Kim WJ, Cheong HJ (2009) Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. J Med Virol 81:722–727

    Article  PubMed  Google Scholar 

  • Kelly H, Grant K (2009) Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 14. pii: 19288

    Google Scholar 

  • Kengsakul K, Sathirapongsasuti K, Punyagupta S (2002) Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85:131–134

    PubMed  Google Scholar 

  • Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM (2004) Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351:2295–2301

    Article  PubMed  CAS  Google Scholar 

  • Khanlou H, Sanchez S, Babaie M, Chien C, Hamwi G, Ricaurte JC et al (2006) The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients. Arch Intern Med 166:1417

    Article  PubMed  Google Scholar 

  • Kunisaki KM, Janoff EN (2009) Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 9:493–504

    Article  PubMed  Google Scholar 

  • Lambert PH, Laurent PR (2008) Intradermal vaccine delivery: Will new delivery systems transform vaccine administration? Vaccine 26:3197–3208

    Article  PubMed  CAS  Google Scholar 

  • Le Borgne M, Etchart N, Goubier A et al (2006) Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 24:191–201

    Article  PubMed  CAS  Google Scholar 

  • Liu YJ (2005) IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23:275–306

    Article  PubMed  CAS  Google Scholar 

  • Lynch HE, Goldberg GL, Chidgey A, Van den Brink MR, Boyd R, Sempowski GD (2009) Thymic involution and immune reconstitution. Trends Immunol 30:366–373

    Article  PubMed  CAS  Google Scholar 

  • Mackenzie JS, Fimmel PJ (1978) The effect of ABO blood groups on the incidence of epidemic influenza and on the response to live attenuated and detergent split influenza virus vaccines. J Hyg (Lond) 80:21–30

    Article  CAS  Google Scholar 

  • Macroepidemiology of Influenza Vaccination (MIV) Study Group (2005) The macro-epidemiology of influenza vaccination in 56 countries, 1997–2003. Vaccine 23:5133–5143

    Article  Google Scholar 

  • Madhi S et al. (2009) Efficacy of influenza vaccine in HIV-infected (HIV+) adults: a double-blind, placebo randomised controlled trial in South Africa. In: 5th IAS conference on HIV pathogenesis, treatment and prevention. 19–22 July 2009, Cape Town. Late breaker poster LBPEB04. http://www.ias2009.org/pag/Abstracts.aspx?AID=3805

  • Manuel O, Humar A, Chen MH et al (2007) Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant 11:2567–2572

    Article  Google Scholar 

  • Mar ID, Niang I, Guicheney A, Berne C, Collomb H, Rey M, Satgé P (1967) Encephalitis following anti-yellow fever vaccination (from 248 cases observed at Dakar in 1965). Ann Pediatr (Paris) 143:181–191

    Google Scholar 

  • Marianneau P, George-Courbot M, Deubel V (2001) Rarity of adverse effects after 17D yellow-fever vaccination. Lancet 358:84–85

    Article  PubMed  CAS  Google Scholar 

  • Mason RA, Tauraso NM, Spertzel RO, Ginn RK (1973) Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25:539–544

    PubMed  CAS  Google Scholar 

  • Mateo RI, Xiao SY, Travassos da Rosa AP, Lei H, Guzman H, Lu L, Tesh RB (2007) Yellow fever 17-D vaccine is neurotropic and produces encephalitis in immunosuppressed hamster. Am J Trop Med Hyg 77:919–924

    PubMed  Google Scholar 

  • McCarroll JR, Kilbourne ED (1958) Immunization with Asian-strain influenza vaccine, equivalence of the subcutaneous and intradermal routes. NEJM 259:618–621

    Article  PubMed  CAS  Google Scholar 

  • McLachlan JB, Shelburne CP, Hart JP et al (2008) Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 14:536–541

    Article  PubMed  CAS  Google Scholar 

  • McMichael AJ, Gotch F, Cullen P, Askonas B, Webster RG (1981) The human cytotoxic T cell response to influenza A vaccination. Clin Exp Immunol 43:276–284

    PubMed  CAS  Google Scholar 

  • Monath TP (2005) Yellow fever vaccine. Expert Rev Vaccines 4:553–574

    Article  PubMed  CAS  Google Scholar 

  • Monath TP (2008a) Yellow fever. In: Plotkin SA, Orenstein WA, Paul A (eds) Vaccines, 5th ed. Saunders Elsevier, Philadelphia, p 959

    Google Scholar 

  • Monath TP (2008b) Treatment of yellow fever. Antiviral Res 78:116–124

    Article  PubMed  CAS  Google Scholar 

  • Monath TP, Cetron MS, McCarthy K et al (2005) Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 1:207–214

    Article  PubMed  Google Scholar 

  • Nicolas JF, Guy B (2008) Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 7:1201–1214

    Article  PubMed  Google Scholar 

  • Niedrig M, Lademann M, Emmerich P, Lafrenz M (1999) Assessment of IgG antibodies against yellow fever firus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 12:867–871

    Article  Google Scholar 

  • Oren S, Mandelboim M, Braun-Moscovici et al (2008) Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 67:937–941

    Article  PubMed  CAS  Google Scholar 

  • World Health Organisation (2003) Yellow fever vaccine. WHO position paper, Wkly Epidemiol Rec 40:349–359

    Google Scholar 

  • Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG (2007) Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat 14:189–193

    Article  PubMed  CAS  Google Scholar 

  • Palmer DR, Fernandez S, Bisbing J et al (2007) Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol 88:148–156

    Article  PubMed  CAS  Google Scholar 

  • Pape KA, Catron DM, Itano AA, Jenkins MK (2007) The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity 26:491–502

    Article  PubMed  CAS  Google Scholar 

  • Pfister G, Savino W (2008) Can the immune system still be efficient in the elderly? An immunological and immunoendocrine therapeutic perspective. Neuroimmunomodulation 15:351–364

    Article  PubMed  CAS  Google Scholar 

  • Pincus S, Mason PW, Konishi E, Fonseca BA, Shope RE, Rice CM, Paoletti E (1992) Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever virus encephalitis. Virology 187:290–297

    Article  PubMed  CAS  Google Scholar 

  • Plotkin SA (2008) Correlates of vaccine-induced immunity. Clin Infect Dis 47:401–409

    Article  PubMed  Google Scholar 

  • Pulendran B, Ahmed R (2006) Translating innate immunity into immunological memory: implications for vaccine development. Cell 124:849–863

    Article  PubMed  CAS  Google Scholar 

  • Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203:413–424

    Article  PubMed  Google Scholar 

  • Roukens AH, Visser LG (2008) Yellow fever vaccine: past, present and future. Expert Opin Biol Ther 8:1787–1795

    Article  PubMed  CAS  Google Scholar 

  • Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG (2008) Intradermally administered Yellow Fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS ONE 3:e1993

    Article  PubMed  Google Scholar 

  • Roukens AH, Vossen AC, van Dissel JT, Visser LG (2009) Reduced intradermal test dose of yellow fever induces protective immunity in individuals with egg allergy. Vaccine 27:2408–2409

    Article  PubMed  CAS  Google Scholar 

  • Russell CA, Jones TC, Barr IG et al (2008) The global circulation of seasonal influenza A (H3N2) viruses. Science 320:340–346

    Article  PubMed  CAS  Google Scholar 

  • Ryan J, Zoellner Y, Gradl B, Palache B, Medema J (2006) Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 24:6812–6822

    Article  PubMed  Google Scholar 

  • Sellards AW (1931) The behaviour of the virus of yellow fever in monkeys and mice. Proc Natl Acad Sci U S A 17:339–343

    Article  PubMed  CAS  Google Scholar 

  • Siegrist CA (2008) Vaccine immunology. In: Plotkin S, Orenstein W, Offit P (eds) Vaccines, 5th edn. Saunders Elsevier, Philadelphia

    Google Scholar 

  • Skobe M, Detmar M (2000) Structure, function, and molecular control of the skin lymphatic system. J Investig Dermatol Symp Proc 5:14–19

    Article  PubMed  CAS  Google Scholar 

  • Smedley J, Poole J, Waclawski E et al (2007) Influenza immunisation: attitudes and beliefs of UK healthcare workers. Occup Environ Med 64:223–227

    Article  PubMed  Google Scholar 

  • Smith W, Andrews C, Laidlaw P (1933) A virus obtained from influenza patients. Lancet 2:66–68

    Article  Google Scholar 

  • Smith DJ, Forrest S, Ackley DH, Perelson AS (1999) Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci U S A 96:14001–14006

    Article  PubMed  CAS  Google Scholar 

  • Stokes A, Bauer JH, Hudson NP (2001) The transmission of yellow fever to Macacus rhesus. Rev Med Virol 11:141–148

    Article  PubMed  CAS  Google Scholar 

  • Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K (2009) Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematol 49:9–13

    Article  Google Scholar 

  • Tasker SA, Treanor JJ, Paxton WB, Wallace MR (1999) Efficacy of influenza vaccination in HIV-infected persons: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 131:430–433

    PubMed  CAS  Google Scholar 

  • Theiler M, Smith HH (1937) The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 65:787–800

    Article  PubMed  CAS  Google Scholar 

  • Treanor JJ (2009) Influenza viruses, including avian influenza and swine influenza. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, 7th edn. Elsevier, Philadelphia

    Google Scholar 

  • van Assen S, Holvast A, Benne CA et al (2010) Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62:75–81

    Article  PubMed  Google Scholar 

  • van der Kolk LE, Baars JW, Prins MH, van Oers MH (2002) Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100:2257–2259

    PubMed  Google Scholar 

  • Veit O, Niedrig M, Chapius-Taillard C, Cavassini M, Mossdorf E, Schmid P, Bae HG, Litzba N, Staub T, Hatz C, Furrer H, Swiss HIV Cohort Study (2009) Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 48:659–666

    Article  PubMed  Google Scholar 

  • Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B (2008) Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 46:1078–1084

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Suite C5-P, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands

    A. H. E. Roukens & L. G. Visser

  2. Department of Internal Medicine, Medisch Centrum Haaglanden, P.O. Box 432, 2501 CK, The Hague, The Netherlands

    L. B. S. Gelinck

Authors
  1. A. H. E. Roukens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. B. S. Gelinck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. G. Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. G. Visser .

Editor information

Editors and Affiliations

  1. , Department of Dermatology, University of Amsterdam, Academic Medica, Meibergdreef 9, Amsterdam, 1105 AZ, Netherlands

    Marcel B.M. Teunissen

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Roukens, A.H.E., Gelinck, L.B.S., Visser, L.G. (2011). Intradermal Vaccination to Protect Against Yellow Fever and Influenza. In: Teunissen, M. (eds) Intradermal Immunization. Current Topics in Microbiology and Immunology, vol 351. Springer, Berlin, Heidelberg. https://doi.org/10.1007/82_2011_124

Download citation

Publish with us

Policies and ethics

Search

Navigation